Clinical Trials Logo
  1. Home
  2. Healthy Volunteers
  3. NCT02825368
  4. Details
NCT02825368 Clinical Trial

Homeopathic Vaccine Trial

Healthy Volunteers Clinical Trial

— HVT  

Official title:
Homeopathic Vaccine Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02825368
Other study ID # HVT-2016
Secondary ID
Status Recruiting
Phase Phase 4
First received June 24, 2016
Last updated August 3, 2017
Start date September 2016

Study information
Verified date August 2017
Source McMaster University
Contact Mark Loeb, MD, MSc.
Phone 905-525-9140
Email loebm@mcmaster.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to compare the immunological response of homeopathic vaccines to placebo and to conventional vaccines in healthy young adults.

Recruitment information / eligibility
Status Recruiting
Enrollment 0
Est. completion date
Est. primary completion date August 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 24 Years
Eligibility Inclusion Criteria:

- Between the ages of 18 and 24 years

- Has received primary childhood DTaP and MMR vaccinations

- Available for a follow up visit (3 weeks after initial visit)

Exclusion Criteria:

- Received a live vaccine in the past 4 weeks

- Has had a serious allergic reaction to a previous vaccination

- Has allergies to one or more of the components of the vaccines to be used (Neomycin, egg protein)

- Has a history of encephalopathy within 7 days of receiving DTP/DTap

- Has received nosodes for Diphtheria, Tetanus, Pertussis, Measles and Mumps

- Has received an adult booster dose of conventional vaccines of diphtheria, pertussis, tetanus, mumps, and measles (Tdap or MMR)

- Has received immunosuppressive doses of steroids or anti-cancer drugs in the past 3 months

- Is pregnant or if there is a chance they could become pregnant during the next month

- Has a moderate to severe acute illness at the time of enrolment

- Has cancer, leukemia, HIV/AIDS, or any other serious immune health condition

- Has a history of Guillaume Barre Syndrome

- Has received blood transfusion, blood products, or immune globulin within the past year

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• MMR
0.5 mL, subcutaneous
• Tdap
0.5 mL, intramuscular
Other:
• Diphtherinum®

• Pertussinum®

• Tetanotxicum®

• Morbilinum®

• Ourlianum®

• Sterile saline
0.5 mL, intramuscular
• Sugar pellets

Locations
Country Name City State
Canada McMaster University Hamilton Ontario

Sponsors (1)
Lead Sponsor Collaborator
McMaster University

Country where clinical trial is conducted

Canada, 

Outcome
Type Measure Description Time frame Safety issue
Primary Antibody levels for diphtheria 3 weeks
Primary Antibody levels for pertussis 3 weeks
Primary Antibody levels for tetanus 3 weeks
Primary Antibody levels for mumps 3 weeks
Primary Antibody levels for measles 3 weeks
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1